Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
Fiche du document
1 octobre 2020
- doi: 10.1097/QAI.0000000000002429
- issn: 1525-4135
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1097/QAI.0000000000002429
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32925387
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1944-7884
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_95A8DFE7C6ED7
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Citer ce document
B. Surial et al., « Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study. », Serveur académique Lausannois, ID : 10.1097/QAI.0000000000002429
Métriques
Partage / Export
Résumé
Whereas tenofovir disoproxil fumarate (TDF) can lead to renal adverse events, tenofovir alafenamide (TAF) has a more favorable renal safety profile. However, the impact of replacing TDF with TAF on renal function and liver parameters among HIV/hepatitis B virus (HBV)-coinfected individuals with renal dysfunction remains unclear. We included all participants from the Swiss HIV Cohort Study with an HIV/HBV coinfection who switched from TDF to TAF and had an estimated glomerular filtration rate (eGFR)